Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Peripheral T-cell lymphoma, confirmed through a laboratory analysis of tumour tissue
- People who have tumour tissue available (either previously collected and stored, or newly collected) that can be used for genetic testing before the study begins
- People whose lymphoma can be measured or assessed using a PET-CT or CT scan
- People who are reasonably physically active and able to care for themselves, based on a standard performance scale (rated 0, 1, or 2 out of 4)
- People with a life expectancy of at least 3 months
- People who are willing and able to give informed consent to participate
Who may not be able to join:
- People who have a type of lymphoma called ALCL (Anaplastic Large Cell Lymphoma) or a skin-based (cutaneous) T-cell lymphoma
- People whose lymphoma has spread to the brain or spinal cord (central nervous system lymphoma)
- People who have had another type of cancer in the past, except for certain common skin cancers (basal cell or squamous cell carcinoma) or a very early-stage cervical condition (carcinoma in situ of the cervix)
- People with uncontrolled heart or blood vessel disease, blood clotting disorders, connective tissue diseases, serious active infections, or other serious medical conditions
- People whose blood test results at the start of the study fall outside acceptable ranges — including low white blood cell or platelet counts, or signs of reduced liver or kidney function — unless those results are caused by the lymphoma itself (confirm with trial site for specific values)
- People living with HIV
- People with an active hepatitis infection
- People with psychiatric conditions, or those who may not be able to follow the study requirements fully
- People who are pregnant or breastfeeding
- People with an active autoimmune disease (this applies specifically to a particular part of the study called T3)
- People whose overall health condition is considered by the research team to make participation unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +862164370045
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Recommended Phase 2 Dose (RP2D) for Phase I; Complete response rate (CRR) for Phase II
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.